【摘要】 目的:比较喹硫平与利培酮对女性精神分裂症的疗效及副作用。方法:将符合CCMD-3精神分裂症诊断标准的67例女性患者随机分为两组,分别给予喹硫平与利培酮治疗,疗程为8周。以阳性症状和阴性症状量表(PANSS)、临床疗效总评量表(CG I)评定疗效、以精神药物副反应量表(TESS)评定副反应。结果:治疗8周后,两组患者的PANSS、CG I评分均明显减少,差异有显著性(P<0.01)。两组间比较PANSS、CG I评分差异无显著性(P>0.05)。喹硫平组副反应发生率低于利培酮组,差异有显著性(P<0.05)。结论:喹硫平与利培酮对女性精神分裂症的疗效相当,有效率分别为81.9%、85.3%。喹硫平锥体外系副反应和内分泌改变较利培酮少,更适用于女性精神分裂症患者。更多还原

【Abstract】 Objective:To compare the curative effect and safety of the therapy scheme to apply quetiapine and risperidone to the female schizophrenia.Methods:67 female patients with schizophrenia by CCMD-3 were randomly allocated to two groups treated with quetiapine or risperidone for 8 week.We evaluate the result by the Positive and Negative Syndrome Scale for schizophrenia(PANSS),the Clinical Global Impression Scale(CGI), the Treatment Emergent Symptom Scale(TESS).Results: By the end of the 8 weeks,the PANSS and CGI scores of two groups decreased notably (P<0.01).There was no significant difference between the two groups(P>0.05).Incidence of adverse effects in the quetiapine group was lower than that in the risperidone group,but the differencewas not significant(P>0.05).Conclusions: The results suggest that quetiapine is as effective as risperidone for the treatment of female schizophrenia;the effective rate of the therapy scheme is 81.9% and 85.3%.The rates of extra-pyramidal symptoms and endocrine change were higher in the risperidone group than those in the quetiapine group.Quetiapine is beneficial for female schizophrenia.更多还原